Andrew J. Krouse
Fondatore presso Cavion, Inc.
Profilo
Andrew J.
Krouse is the founder of Cavion, Inc., which was founded in 2005.
He is currently the President & Chief Executive Officer at Slate Bio, Inc. and GenEp, Inc. He is also the Director at The Virginia Bioscience Foundation since 2018.
Mr. Krouse previously held the position of Director at the Virginia Biotechnology Association from 2014 to 2017.
He also held Vice President positions at the University of Virginia and the Darden School Foundation.
Mr. Krouse completed his undergraduate degree at the University of Maryland and his graduate degree at Georgetown University.
Posizioni attive di Andrew J. Krouse
| Società | Posizione | Inizio |
|---|---|---|
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Fondatore | 03/08/2009 |
| The Virginia Bioscience Foundation | Direttore/Membro del Consiglio | 01/01/2018 |
Slate Bio, Inc.
 Slate Bio, Inc. BiotechnologyHealth Technology Slate Bio, Inc. is a pre-clinical stage biotechnology company that focuses on developing therapies to restore the body's natural immunological response in various diseases. The company is based in Charlottesville, VA. The company's lead compound is a bifunctional IL233 cytokine that augments Tregs and expands tissue resident Tregs. The CEO of the company is Andrew J. Krouse. | Amministratore Delegato | - |
GenEp, Inc.
 GenEp, Inc. BiotechnologyHealth Technology GenEp, Inc. is a pre-clinical stage biotechnology company that aims to create therapies for rare genetic epilepsies and other treatment-resistant epilepsies. The company is based in Charlottesville, VA and was founded in 2021. The company is privately held and is based on intellectual property assets licensed from the University of Virginia. The CEO is Andrew J. Krouse. | Amministratore Delegato | - |
Precedenti posizioni note di Andrew J. Krouse
| Società | Posizione | Fine |
|---|---|---|
| Darden School Foundation | Corporate Officer/Principal | - |
Virginia Biotechnology Association
 Virginia Biotechnology Association Miscellaneous Commercial ServicesCommercial Services Virginia Biotechnology Association promotes the biotechnology industry. The private company is based in Richmond, VA. The company was founded in 1992 by Terry R. Woodworth. John L. Newby has been the CEO of the company since 2019. | Presidente | - |
| University of Virginia | Corporate Officer/Principal | - |
Formazione di Andrew J. Krouse
| University of Maryland | Undergraduate Degree |
| Georgetown University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Cavion, Inc.
Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Health Technology |
| Darden School Foundation | |
Virginia Biotechnology Association
Virginia Biotechnology Association Miscellaneous Commercial ServicesCommercial Services Virginia Biotechnology Association promotes the biotechnology industry. The private company is based in Richmond, VA. The company was founded in 1992 by Terry R. Woodworth. John L. Newby has been the CEO of the company since 2019. | Commercial Services |
| The Virginia Bioscience Foundation | |
Slate Bio, Inc.
Slate Bio, Inc. BiotechnologyHealth Technology Slate Bio, Inc. is a pre-clinical stage biotechnology company that focuses on developing therapies to restore the body's natural immunological response in various diseases. The company is based in Charlottesville, VA. The company's lead compound is a bifunctional IL233 cytokine that augments Tregs and expands tissue resident Tregs. The CEO of the company is Andrew J. Krouse. | Health Technology |
GenEp, Inc.
GenEp, Inc. BiotechnologyHealth Technology GenEp, Inc. is a pre-clinical stage biotechnology company that aims to create therapies for rare genetic epilepsies and other treatment-resistant epilepsies. The company is based in Charlottesville, VA and was founded in 2021. The company is privately held and is based on intellectual property assets licensed from the University of Virginia. The CEO is Andrew J. Krouse. | Health Technology |
- Borsa valori
- Insiders
- Andrew J. Krouse
